Note: Veriheal does not support illegally consuming therapeutic substances like psilocybin magic mushrooms but acknowledges that it transpires because of the current illicit status of both, which we strive to change by advocating for research, legal access, and responsible consumption. Always consult a physician before attempting alternative therapies.
The National Institute of Mental Health estimates that there are around 19.4 million adults in America who’ve faced at least one depressive episode in their lifetime – most of which are able to improve through the help of antidepressant treatments (9). However, there are still many others who are faced with treatment-resistant depression that remains persistent despite efforts for improvement.
Treatment-resistant depression is when an individual with depression does not adequately respond to standard treatments. In other words, treatment for depression is not sufficiently alleviating their symptoms after 1 or more trials of antidepressants or counseling. Normally, an individual would be taking antidepressants for 6-8 weeks and/or undergoing psychological counseling – which would then begin to alleviate the depression. So what happens when your depression is not responding to months of treatment?
Leading health organizations such as The Mayo Clinic and the American Academy of Family Physicians often outline strategies, several of which are medication-based and combined with psychotherapy (6) (5). Those strategies include giving current medication more time, increasing the dose, and switching antidepressants…so many pharmaceuticals which are all associated with side effects such as nausea, weight gain, blurred vision, insomnia, loss of sexual drive, etc. It may normally take several months to find the right medication and dosage for you, which takes patience and commitment. Fortunately, recent research on psilocybin shows promise for how using the botanical substance may help alleviate treatment-resistant depression.
The acclaimed author of Harry Potter, J.K Rowling, stated that “It’s so difficult to describe depression to someone who’s never been there because it’s not sadness. I know sadness. Sadness is to cry and to feel. But it’s that cold absence of feeling—that really hollowed-out feeling (7).” Depression can be lonely and even dangerous when left unchecked- which is what makes finding alleviation for treatment-resistant depression so vital.
For more on depression, be sure to check out this article.
In order to understand how psilocybin can assist with treatment-resistant depression (TRD), let’s have a look at this 2021 published study which found that psilocybin may work as effectively as escitalopram, a common antidepressant– now I know what you’re thinking… “How can such a substance assist when they may only work as effectively as the current medication proved ineffective for this type of depression (2)?” Well, let’s find out.
The study compared the effectiveness of commonly prescribed antidepressants with therapeutic doses of psilocybin (2). While the study did find psilocybin effective for depression, it also found a significant difference in antidepressant effects between psilocybin and escitalopram (a common antidepressant). The secondary outcomes also generally favored psilocybin, though not statistically corrected for.
Despite the fact that psilocybin did not prove to be more effective than antidepressants, another study found that two doses of psilocybin were more effective than common treatments in terms of assisting with TRD (3). In both of these studies, patients also received psychological support. The TRD study conducted theirs on the basis that “clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy (3).”
Researchers Carhart-Harris (also first author of the 2021 study), Bolstridge, Day, and the team sought to report on the safety and efficacy of the outcomes of psilocybin on TRD for up to six months in an open-label trial. The team of researchers found that the psilocybin was well tolerated by the participants and that reductions in depressive symptoms were observed within1-5 weeks post-treatment. At the same time, 5 weeks post-treatment, “nine and four patients met the criteria for response and remission at week 5 (1).”
Additionally, at the 5-week mark, none of the participants sought out further antidepressant treatment after having been treated with psilocybin. When assessing the participants again, the team found a continuing positive response to the psilocybin at 3 and 6 months. After 3 months, a few patients sought out additional treatments including antidepressants (6 patients), therapy (5 patients), or more psilocybin (5 patients) (1).
The team concluded by stating that despite the limited conclusions which can be made from an open-label trial, they found that “tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort (1).”
The relationship between serotonin and depression is explained by the fact that serotonin is the brain’s “happy” chemical that influences mood. Higher levels of serotonin are linked to elevated mood and feeling happy, whereas lower levels of serotonin are linked to sadness and depression (8).
The psilocybin in magic mushrooms, or shrooms, has the ability to deliver mind-altering, neuroplastic effects which is why people with depression can benefit from the substance. psilocybin has a high affinity for several serotonin receptors which are located in numerous areas of the brain, including the cerebral cortex and thalamus (1).
Since psilocybin has a “high affinity” for the receptors of this “happy” chemical, it stands to reason that psilocybin can boost the chemical, thereby gearing consumers towards the state associated with higher levels of serotonin (1). This is what researchers are confirming and why it makes for a viable and effective means of alleviating depression. Psilocybin and other serotonergic psychedelics may also help rewire brain connections, a property called neuroplasticity, which could explain its lasting effects months after consumption (4). Unfortunately, limited research is being conducted since the substance is still widely illegal.
Psilocybin is quickly gaining support for its continued promise as a powerful therapeutic substance with the potential to alleviate an array of conditions – much like cannabis. At the moment, it is anyone’s guess as to whether the psilocybin will be removed from its federally-imposed Schedule 1 listing. Fortunately, research such as this provides hope where some may feel there is none- such as is the case in treatment-resistant depression.
1. Carhart-Harris, R.L., Bolstridge, M., Day, C.M.J. et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology 235, 399–408 (2018). https://link.springer.com/article/10.1007/s00213-017-4771-x
2. Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. New England Journal of Medicine, 384(15), 1402–1411. https://www.nejm.org/doi/full/10.1056/NEJMoa2032994
3. Daniel, J., & Haberman, M. (2018). Clinical potential of psilocybin as a treatment for mental health conditions. The mental health clinician, 7(1), 24–28. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007659/
4. De Vos, C. M., Mason, N. L., & Kuypers, K. P. (2021). Psychedelics and neuroplasticity: A systematic review unraveling the biological underpinnings of psychedelics. Frontiers in Psychiatry, 12. https://www.frontiersin.org/articles/10.3389/fpsyt.2021.724606/full
5. Maurer, D. M., Raymond, T. J., & Davis, B. N. (2018, October 15). Depression: Screening and diagnosis. American Family Physician. Retrieved January 2, 2022, from https://www.aafp.org/afp/2018/1015/p508.html
6. Mayo Foundation for Medical Education and Research. (2018, February 3). Depression (major depressive disorder). Mayo Clinic. Retrieved January 2, 2022, from https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007
7. Pocha, S. K. (2016, February 9). J.K. Rowling offers touching advice to a fan suffering depression. Stylist. Retrieved January 2, 2022, from https://www.stylist.co.uk/people/j-k-rowling-gives-touching-advice-to-a-fan-suffering-depression-anxiety/27011
8. Priory Group. (n.d.). What is the link between serotonin and depression? Priory. Retrieved January 2, 2022, from https://www.priorygroup.com/blog/what-is-the-link-between-serotonin-and-depression
9. U.S. Department of Health and Human Services. (2021, October). Major depression. National Institute of Mental Health. Retrieved January 2, 2022, from https://www.nimh.nih.gov/health/statistics/major-depression#:~:text=An%20estimated%2017.3%20million%20adults,compared%20to%20males%20(5.3%25)
The flowering buds of the cannabis plant have always been the star of the show due to their high concentration of cannabinoids like THC and CBD that create effects for consumers. But what many don’t know is that other parts of the plant—specifically the trim removed after harvesting—can be used for a variety of purposes….
Thinking about magic mushrooms takes me back to my teenage years when we would pick liberty caps from farmers’ fields. Liberty caps offered a great free buzz at the time in my life when I started to understand these substances to be a mind-expanding one as well. What started out as fun and giggles eventually…
Can you imagine what it is like to be overcome with intense feelings of euphoria? In the midst of all the madness caused by the motions of life, you take a pill and suddenly everything is brighter, more magical, and just feels so darn good? It turns out that this blissful drug, MDMA, has the…
Many states across the U.S. have legalized cannabis for medical and retail consumption. The regulations governing these industries primarily focus on the products’ content of the two most prominent cannabinoids found in the cannabis plant, cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC). But in recent months, a new cannabinoid known as delta-8-tetrahydrocannabinol (delta-8 THC) has entered the…
Ketamine, with its “triple-threat of sedative, stimulating, and psychedelic effects,” according to The Cut, has a wild and elusive history. First approved by the U.S. Food and Drug Administration (FDA) in 1970 as a wartime anesthetic, ketamine turned into a popular party drug feared by parents everywhere before eventually being considered as a treatment for…
Louisiana’s medical cannabis expansion has gotten mixed reviews, Mississippi’s proposed legalization legislation may be too good to be true, and Colorado cemented…
A new report carried out by drug policy reform organization Volteface suggests that the United Kingdom could be leaving £1.2 billion on…
Most of us are no strangers to the stress imposed on us as a result of the coronavirus pandemic. Multiple studies from…